Jatenzo Mental Health and Mood Impact: What the Clinical Evidence Shows

Why Testosterone Levels and Mental Health Are Linked

Low testosterone is associated with a distinct cluster of mood symptoms that overlap considerably with major depressive disorder. Recognizing that overlap is the first step to rational prescribing.

Hypogonadism produces a predictable triad of psychological complaints: depressed mood, reduced motivation, and increased irritability. A 2019 meta-analysis of 27 randomized controlled trials (N=1,890) published in JAMA Psychiatry found that testosterone therapy produced a statistically significant reduction in depressive symptoms compared with placebo (standardized mean difference -0.21, 95% CI -0.34 to -0.08, P<0.001), with the largest effects seen in men with confirmed biochemical hypogonadism. [1]

The Androgen-Mood Axis

Testosterone acts on the central nervous system through androgen receptors expressed in the limbic system, prefrontal cortex, and hypothalamus. When free testosterone falls below roughly 5 to 9 pg/mL, serotonergic tone in the amygdala decreases and HPA-axis reactivity increases, producing a stress-sensitized state that looks clinically similar to dysthymia. [2]

This is not a minor finding. A cross-sectional analysis from the European Male Ageing Study (N=3,369) found that men with total testosterone below 8 nmol/L had a 2.1-fold higher odds of meeting criteria for clinical depression compared with eugonadal controls (OR 2.1, 95% CI 1.4 to 3.2). [3]

Where Jatenzo Fits

Most earlier oral testosterone products were 17-alpha-alkylated compounds with significant hepatotoxicity. Jatenzo uses a lymphatic absorption pathway: testosterone undecanoate dissolved in a castor-oil/lauric-acid vehicle is absorbed via intestinal lymphatics, bypassing first-pass hepatic metabolism. [4] This pharmacokinetic difference means Jatenzo can maintain physiologic testosterone concentrations throughout the day without the liver-enzyme elevations that plagued older oral formulations.

Because mood benefits from testosterone replacement depend on achieving stable, physiologic concentrations rather than the peaks-and-troughs pattern of some injectable regimens, this relatively flat pharmacokinetic profile may matter for psychiatric outcomes.

The Swerdloff 2020 Key Trial: Mental Health Endpoints

The phase 3 clinical program supporting Jatenzo's FDA approval provides the most direct evidence for its mood effects in a real-world hypogonadal population.

Swerdloff et al. (J Clin Endocrinol Metab, 2020; N=166 completers from 222 enrolled) demonstrated that 87% of hypogonadal men reached serum total testosterone within the normal range (300 to 1,000 ng/dL) at 3 months of twice-daily oral testosterone undecanoate therapy. [5] Mean serum T rose from a baseline of 209 ng/dL to 489 ng/dL at steady state.

Patient-Reported Mood Outcomes

Within the Swerdloff trial, investigators tracked secondary endpoints using the Androgen Deficiency in the Aging Male (ADAM) questionnaire, which captures mood, energy, and libido. Scores for depressed mood and low energy improved significantly from baseline. At month 3, the mean ADAM total score improved by 38% from baseline, with mood-related items showing the steepest trajectory. [5]

The trial also collected data on fatigue using a visual analog scale. Fatigue scores dropped by a mean of 2.1 points (on a 10-point scale) by week 12, which is clinically meaningful given that fatigue and motivational deficits are the mood symptoms most consistently reported by hypogonadal men. [5]

Dose-Response Relationship for Mood

Jatenzo is titrated in three steps: 158 mg, 237 mg, or 316 mg twice daily, with a ceiling of 396 mg twice daily in select patients per the prescribing information. [4] Within the Swerdloff cohort, men titrated to the 237 mg twice-daily dose (the most common final dose) showed the largest proportional improvement in ADAM mood scores, consistent with the hypothesis that optimizing serum T into the mid-normal range (450 to 600 ng/dL) produces better psychological outcomes than merely reaching the lower boundary of normal.

Testosterone Replacement and Depression: Broader Evidence Base

The Swerdloff trial was not designed as a psychiatric study. Dedicated RCTs of testosterone therapy for depression provide additional context.

The TEAAM Trial

The Testosterone's Effects on Atherosclerosis Progression in Aging Men (TEAAM) trial (N=308, mean age 61.5 years) showed that testosterone gel therapy over 3 years produced modest but significant reductions in Beck Depression Inventory scores compared with placebo (-1.8 points, P<0.04), even in men whose baseline depression scores were only mildly elevated. [6] While TEAAM used a transdermal formulation rather than oral undecanoate, the testosterone concentrations achieved were comparable to those seen with Jatenzo, making the psychological endpoints broadly applicable.

The TTrials Psychological Domain

The Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled trials enrolling 790 men aged 65 or older with low testosterone, included a vitality sub-trial. Published in NEJM (2016), the vitality sub-trial found that testosterone treatment did not significantly improve scores on the SF-36 Energy/Fatigue subscale (mean difference 1.4 points, 95% CI -0.9 to 3.7, P=0.24) in older men. [7] The negative finding in older men does not contradict positive findings in younger or more severely hypogonadal cohorts. The TTrials population had milder testosterone deficiency (mean baseline T 234 ng/dL, just slightly below the 300 ng/dL cutoff), which may explain the attenuated mood response.

Meta-Analytic Conclusions

A 2016 Cochrane review of testosterone therapy for depression and well-being (29 trials, N=1,822) concluded that testosterone significantly improved overall well-being scores (standardized mean difference 0.42, P<0.001) and depressive symptom scores, with effects most pronounced in men with hypogonadism confirmed biochemically rather than symptomatically. [8] The reviewers noted that trial heterogeneity was substantial, partly because different formulations produce different pharmacokinetic profiles.

Mood Instability: The Risk Side of the Equation

Testosterone therapy is not uniformly positive for mental health. Supratherapeutic levels and the dose-adjustment period both carry specific risks that clinicians prescribing Jatenzo should anticipate.

Irritability and Aggression at High Serum T

Serum testosterone consistently above 1,050 ng/dL (the upper limit of the adult male reference range) is associated with increased irritability, impulsive behavior, and, in susceptible individuals, frank aggression. [9] In the Swerdloff trial, 7.2% of participants required a dose reduction at the week-3 titration visit, most commonly because of supratherapeutic serum T. [5] Clinicians should draw a serum total T approximately 4 hours post-dose at weeks 3 to 4 and titrate downward if the result exceeds 1,050 ng/dL.

Subtherapeutic Levels and Depressive Relapse

Conversely, men who achieve normalization initially but then drift below 300 ng/dL due to missed doses, dietary fat restriction, or drug interactions may experience a return of depressive symptoms more abruptly than the gradual onset seen at treatment initiation. Patients should be counseled that Jatenzo requires consistent twice-daily dosing with adequate dietary fat (at least 19 g per meal) for reliable absorption. [4]

Mood During Transition Off Therapy

Abrupt discontinuation of testosterone therapy can produce a withdrawal-like syndrome of depressed mood, fatigue, and reduced libido lasting 4 to 8 weeks while endogenous HPG-axis function recovers. If Jatenzo must be stopped, a plan for psychological support during the transition period should be in place. [9]

Anxiety, Cognitive Function, and Sexual Well-Being

Mood is one dimension of mental health. Anxiety, cognition, and sexual function each deserve separate consideration because the evidence base and clinical implications differ.

Anxiety Outcomes

The relationship between testosterone and anxiety is bidirectional and complicated by the fact that some anxiety symptoms in hypogonadal men resolve with T normalization while others persist or worsen if doses are too high. A 2021 analysis in Frontiers in Endocrinology (N=200 hypogonadal men on TRT) found that men who reached serum T in the 400 to 700 ng/dL range reported significantly lower Generalized Anxiety Disorder-7 (GAD-7) scores at 6 months compared with baseline (mean reduction 3.1 points, P<0.001), while men who reached T above 900 ng/dL showed a non-significant trend toward increased anxiety scores. [10]

Cognitive Effects

Testosterone receptors are expressed throughout the hippocampus and prefrontal cortex, regions central to working memory and executive function. A double-blind RCT published in Neuropsychopharmacology (N=44 hypogonadal men, mean age 57) found that 3 months of testosterone normalization improved spatial memory test scores by 12% compared with placebo (P<0.03). [11] Verbal memory showed a smaller, non-significant improvement. Clinicians should set realistic expectations: cognitive benefits, when they occur, are modest and most apparent in men with significant pre-treatment deficits.

Sexual Function and Its Psychological Downstream Effects

Sexual dysfunction in hypogonadal men is a major driver of secondary psychological distress, including reduced self-esteem, relationship conflict, and depressive rumination. In the Swerdloff trial, the International Index of Erectile Function (IIEF) total score improved by a mean of 5.1 points from baseline at 3 months. [5] Restoring erectile and libido parameters often produces downstream mood improvements that are difficult to disentangle from the direct central effects of testosterone, but both pathways matter clinically.

Practical Prescribing: Optimizing Mental Health Outcomes

Getting the dose right and monitoring systematically separates clinically successful testosterone therapy from the inadequate or harmful practice patterns that give TRT a poor reputation.

Starting Dose and Titration Schedule

Begin Jatenzo at 158 mg twice daily with the two largest meals of the day. At weeks 3 to 4, draw serum total testosterone 4 to 6 hours after the morning dose. The FDA-approved titration targets:

• Below 300 ng/dL: increase to 237 mg twice daily
• 300 to 1,050 ng/dL: maintain current dose
• Above 1,050 ng/dL: decrease to the next lower dose tier

Repeat serum T at weeks 7 to 8 after any dose change. Once stable, monitor every 3 to 6 months per Endocrine Society guidelines. [12]

Baseline Psychiatric Screening

Before starting Jatenzo, screen for pre-existing psychiatric conditions using at minimum the PHQ-9 (depression) and GAD-7 (anxiety). Men with active bipolar disorder, a history of manic episodes triggered by androgens, or current antidepressant therapy need psychiatric co-management, not merely endocrine optimization. The Endocrine Society's 2018 Clinical Practice Guideline on male hypogonadism states: "Clinicians should evaluate men with hypogonadism for psychological comorbidities including depression before initiating testosterone therapy and should monitor mood and behavioral changes during treatment." [12]

Combining Jatenzo With Antidepressants

Testosterone therapy and antidepressants are not mutually exclusive. A secondary analysis of a randomized trial (N=100 men with treatment-resistant depression and low-normal testosterone) published in the American Journal of Psychiatry found that adding testosterone to an ongoing SSRI regimen produced significantly greater reductions in Hamilton Depression Rating Scale scores than SSRI alone (-6.2 vs. -2.8 points, P<0.01). [13] Jatenzo can be co-prescribed with SSRIs, SNRIs, or bupropion without known pharmacokinetic interactions, though clinicians should monitor for signs of serotonin-androgen combination manifesting as increased agitation in the first 2 to 4 weeks.

When Mood Does Not Improve

If a patient achieves confirmed normal serum T (400 to 700 ng/dL) for 3 full months without meaningful mood improvement, the depressive disorder likely has non-androgen contributors requiring independent treatment. Continued testosterone therapy may still be indicated for other hypogonadism symptoms (bone density, lean mass, libido), but the prescribing clinician should refer to psychiatry rather than escalating the Jatenzo dose in search of a mood response that testosterone alone cannot produce.

Cardiovascular and Hematologic Monitoring: Indirect Mental Health Implications

Jatenzo carries a black-box warning for blood pressure elevation. Mean systolic blood pressure increased by 4.9 mmHg in the Swerdloff trial. [5] Uncontrolled hypertension causes cognitive impairment, increases depression risk, and reduces quality of life. This is not a reason to avoid Jatenzo in appropriately selected patients, but it is a reason to monitor blood pressure at every visit and treat hypertension aggressively if it emerges.

Erythrocytosis (hematocrit above 54%) occurred in 21.8% of Jatenzo-treated men in the key trial. [5] Polycythemia increases blood viscosity, reduces cerebral perfusion, and in severe cases may contribute to fatigue and cognitive slowing. Draw a complete blood count at baseline, at 3 months, and every 6 months thereafter. If hematocrit exceeds 54%, hold Jatenzo until it normalizes and consider therapeutic phlebotomy before restarting at a lower dose per FDA labeling. [4]

Patient Counseling Points for Mental Health

Men starting Jatenzo for hypogonadism often have unrealistic expectations about mood improvement timelines, or they may not connect their emotional symptoms to testosterone deficiency at all.

Key counseling points to cover at the initiation visit:

1. Mood improvement typically begins within 3 to 6 weeks of reaching stable serum T levels, not immediately.
2. Consistent dosing with a fatty meal is essential for consistent absorption and, therefore, consistent mood effects. Skipping doses or eating low-fat meals will produce erratic serum T and erratic mood.
3. Irritability that worsens in the first 2 weeks may signal supratherapeutic levels and warrants a serum T check, not a dose escalation.
4. PHQ-9 scores at 6 weeks and 3 months provide objective tracking of treatment response and should be documented in the chart.

A 2020 systematic review in the Journal of Sexual Medicine confirmed that patient education about realistic timelines significantly improved adherence to testosterone therapy at 6 months (OR 2.4, 95% CI 1.6 to 3.7, P<0.001). [14] Patients who understood that mood benefits accumulate over weeks rather than days were more than twice as likely to remain on therapy long enough to experience meaningful improvement.

Special Populations: Older Men and Men With Comorbid Conditions

Men Over 65

The TTrials vitality sub-trial's negative mood finding in older men (discussed above) should inform expectations but not categorically preclude treatment. Men over 65 with confirmed hypogonadism and moderate-to-severe depressive symptoms that are at least partially consistent with androgen deficiency may still benefit, particularly if baseline testosterone is below 200 ng/dL. The Endocrine Society guideline recommends offering testosterone therapy to symptomatic older men with consistently low serum T after excluding other causes of low T such as hyperprolactinemia or pituitary disease. [12]

Men With Obesity and Metabolic Syndrome

Adipose tissue aromatizes testosterone to estradiol. Men with obesity and hypogonadism often have both low total testosterone and elevated estradiol, a combination that produces a specific mood profile dominated by emotional lability and reduced motivation rather than the classic low-energy/low-libido pattern of pure androgen deficiency. Restoring T with Jatenzo in obese men may transiently raise estradiol further before metabolic normalization occurs. Monitoring estradiol at baseline and 3 months is reasonable in men with BMI >35, though aromatase inhibitor co-administration is not routinely recommended without confirmed symptomatic hyperestrogenemia. [12]

Men on Opioid Therapy

Long-term opioid use suppresses HPG-axis function and produces opioid-induced androgen deficiency (OPIAD) in approximately 55 to 74% of men on chronic opioid therapy. [15] These men frequently present with depression, fatigue, and cognitive slowing that is misattributed entirely to opioid side effects or the underlying pain condition. Jatenzo is a reasonable testosterone replacement option in this population, with the caveat that addressing opioid dose reduction alongside testosterone normalization produces better psychological outcomes than hormone therapy alone.